From Name:
From Email:
To Name:
To Email:

Optional Message:


Macitentan does not reduce incidence of ischemic digital ulcers in patients with systemic sclerosis

from 2 Minute Medicine

Systemic sclerosis is a chronic autoimmune disease that manifests with digital ischemia, arterial hypertension and renal crisis, among others. Digital ulcers, secondary to digital ischemia, are common in this disease, and are associated with pain, disability and poor quality of life. Endothelin-1 is a mediator of vascular hypertrophy, inflammation and fibrosis, and its role has been hypothesized in the development of digital ulcers. This clinical trial tested an endothelin-1 blocker, macitentan, in patients with systemic sclerosis, and found that it was no more effective than placebo in reducing the rate of new digital ulcers. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063